Advanced Biomed (ADVB) vs MDxHealth SA (MDXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Advanced Biomed (ADVB) has outperformed MDxHealth SA (MDXH) over the past year, losing 34.9% versus a loss of 87.2%. MDxHealth SA is the larger company by market cap ($55.4 million vs $10.1 million), about 5.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADVB | MDXH |
|---|---|---|
| Share price | $6.12 | $0.5805 |
| Market cap | $10.11M | $55.39M |
| 1-day change | -2.86% | -3.22% |
| YTD return | +4.79% | -83.74% |
| 1-year return | -34.89% | -87.16% |
| P/E ratio (TTM) | 1.26 | — |
| EPS (TTM) | $4.85 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.23 | $5.33 |
| 52-week low | $3.61 | $0.40 |
| Distance from 52-week high | -74.74% | -89.11% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +210.08% |
| Average volume | 1.75M | 5.70M |
| Shares outstanding | 1.65M | 95.42M |
| Employees | 31 | 364 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDxHealth SA is about 5.5 times larger than Advanced Biomed by market value ($55.39M vs $10.11M).
- ADVB has outperformed MDXH by 52.3 percentage points over the past year.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Healthcare · Diagnostics & Research · 31 employees
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Healthcare · Diagnostics & Research · 364 employees
ADVB vs MDXH FAQ
Which is bigger, Advanced Biomed or MDxHealth SA?
MDxHealth SA (MDXH) is larger, with a market capitalization of $55.39M compared with $10.11M for Advanced Biomed (ADVB).
Which stock has performed better over the past year, ADVB or MDXH?
ADVB returned -34.89% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are Advanced Biomed and MDxHealth SA in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.